![]() |
市場調査レポート
商品コード
1660681
生検装置市場レポート:手技タイプ、製品、用途、ガイダンス技術、エンドユーザー、地域別、2025年~2033年Biopsy Devices Market Report by Procedure Type, Product, Application, Guidance Technique, End User, and Region 2025-2033 |
||||||
カスタマイズ可能
|
生検装置市場レポート:手技タイプ、製品、用途、ガイダンス技術、エンドユーザー、地域別、2025年~2033年 |
出版日: 2025年02月10日
発行: IMARC
ページ情報: 英文 141 Pages
納期: 2~3営業日
|
生検装置の世界市場規模は2024年に28億米ドルに達しました。今後、IMARC Groupは、市場は2033年までに46億米ドルに達し、2025年から2033年にかけて5.47%の成長率(CAGR)を示すと予測しています。がん罹患率の上昇、個別化医療への嗜好の高まり、患者の快適性と回復時間の短縮を目的とした低侵襲手技の推進は、市場を推進する主な要因の一部です。
生検装置は、診断目的で患者の体内から組織サンプルを採取するために特別に設計された医療器具です。様々なヘルスケア現場で広く使用されており、がん、感染症、炎症性疾患など幅広い疾患の診断に役立っています。針生検装置、鉗子生検装置、真空アシスト生検装置などさまざまなタイプがあり、それぞれが特定の医療ニーズに対応しています。超音波、CTスキャン、MRIのようなリアルタイムの画像診断技術を用いることで、ヘルスケア専門家は組織を採取する必要がある場所を正確に特定することができ、手技の成功率を向上させることができます。その結果、生検装置は現代の診断医療に不可欠なツールとして絶大な支持を集め、正確でタイムリーな介入を容易にしています。
診断に生検を必要とする疾患に罹患しやすい高齢化社会は、予測期間中の市場成長を刺激するであろう。加えて、個別化医療への注目の高まりは、疾患の進行をモニターし、それに応じて治療計画を適応させるために、しばしば複数回の生検を必要とするため、生検装置の使用頻度を増加させる。これに伴い、患者の快適性と回復時間の短縮を目的とした低侵襲手技の世界の推進により、これらの低侵襲手技用に設計された生検装置の採用が加速しています。さらに、いくつかの国々におけるヘルスケア支出の増加と支援的な償還政策が市場成長に寄与しています。世界中の政府や民間保険会社がより良いヘルスケアサービスの提供を目指しているため、生検のような診断手技に対する償還の可能性が高くなり、患者にとってより利用しやすいものとなって市場成長を後押ししています。
がん罹患率の上昇
世界のがん罹患率の増加は、生検装置市場の重要なドライバーです。がんの診断には、最適な治療のために正確かつ早期の同定が必要であり、生検は不可欠な診断ツールとなっています。世界保健機関(WHO)によると、がんは世界第2位の死因であり、2018年には推定960万人が死亡しています。がんの発生率が上昇を続ける中、正確で効率的な診断方法の必要性が高まっています。そのため、生検装置は悪性組織の特定に不可欠なものとなりつつあり、臨床医が適切な治療計画を立てることができるようになっています。がん罹患率の上昇は、高度な生検装置の需要を喚起し、市場成長にプラスの影響を与えています。
急速な技術進歩
生検装置の技術革新は、もう一つの大きな成長促進要因です。技術の進歩は生検手技の有効性、スピード、安全性を向上させています。例えば、真空アシスト生検装置は、より迅速で快適な組織サンプルの抽出を可能にし、それによって患者の経験を向上させています。さらに、超音波、CTスキャン、MRIなどのリアルタイム画像診断技術を生検装置に統合することで、医師はより正確な標的部位を得ることができ、手技の合併症を減らし、診断の信頼性を高めることができます。このような技術的強化は、ヘルスケア専門家による製品採用率の向上に寄与し、ひいては市場の成長を後押ししています。
ヘルスケア・インフラへの大規模投資
新興国を中心にヘルスケアインフラへの投資が増加していることも、市場の成長を後押ししています。公的機関や民間機関による資金提供の増加は、診断ラボや最先端の医療機器の購入を含む医療施設の近代化を促進しています。ヘルスケアシステムが世界的に、より正確でタイムリーな診断を提供することに注力しているため、高度な生検装置の導入は自然な流れとなっています。このことは、患者にとって質の高い診断手技への幅広いアクセスを確保する一方で、これらの機器の市場を拡大し、市場成長にプラスの推進力をもたらしています。
The global biopsy devices market size reached USD 2.8 Billion in 2024. Looking forward, IMARC Group expects the market to reach USD 4.6 Billion by 2033, exhibiting a growth rate (CAGR) of 5.47% during 2025-2033. The rising prevalence of cancer, increasing preference for personalized medicine, and the push toward minimally invasive procedures for patient comfort and quicker recovery times are some of the major factors propelling the market.
Biopsy devices are medical instruments specifically designed for extracting tissue samples from a patient's body for diagnostic purposes. They are widely used in various healthcare settings and are instrumental in diagnosing a wide range of conditions, including cancer, infections, and inflammatory diseases. They are available in different types, such as needle, forceps, and vacuum-assisted biopsy devices, each serving particular medical requirements. By employing real-time imaging techniques like ultrasound, CT scans, or MRI, healthcare professionals can pinpoint the exact location from which the tissue needs to be taken, thereby improving the procedure's success rate. As a result, biopsy devices have gained immense traction as indispensable tools in modern diagnostic medicine, facilitating precise and timely interventions.
The aging population, which is more susceptible to diseases requiring biopsy for diagnosis, will stimulate market growth during the forecast period. Additionally, the heightened focus on personalized medicine, which often necessitates multiple biopsy procedures to monitor the disease's progression and adapt the treatment plan accordingly, increases the frequency of biopsy device usage. In line with this, the global push toward minimally invasive procedures for patient comfort and quicker recovery times has accelerated the adoption of biopsy devices designed for these less intrusive techniques. Furthermore, the rising healthcare expenditure and supportive reimbursement policies in several countries are contributing to market growth. As governments and private insurers across the globe aim to provide better healthcare services, there is a higher likelihood of reimbursements for diagnostic procedures like biopsies, making them more accessible to patients fueling the market growth.
Rising Incidence of Cancer
The increasing burden of cancer worldwide is a significant driver for the biopsy devices market. Cancer diagnoses require precise and early-stage identification for optimal treatment, making biopsies an essential diagnostic tool. According to the World Health Organization, cancer is the second leading cause of death globally, responsible for an estimated 9.6 million deaths in 2018. As cancer rates continue to escalate, there has been a rise in the need for accurate and efficient diagnostic methods. Therefore, biopsy devices are becoming vital in identifying malignant tissues, allowing clinicians to formulate appropriate treatment plans. The rising incidence of cancer catalyzes the demand for advanced biopsy devices, thus positively influencing market growth.
Rapid Technological Advancements
Innovations in biopsy devices represent another major growth-inducing factor. Technological advancements are improving the efficacy, speed, and safety of biopsy procedures. For instance, vacuum-assisted biopsy devices allow quicker and more comfortable extraction of tissue samples, thereby enhancing patient experience. Additionally, the integration of real-time imaging techniques such as ultrasound, CT scans, or MRI with biopsy devices provides physicians with a more accurate target area, reducing procedural complications and increasing diagnostic reliability. Such technological enhancements contribute to higher product adoption rates among healthcare professionals, which in turn is propelling market growth.
Extensive Investments in Healthcare Infrastructure
The rising investments in healthcare infrastructure, especially in emerging economies, also drive the market toward growth. The increased funding by public and private agencies facilitates the modernization of medical facilities, including diagnostic labs and the acquisition of state-of-the-art medical equipment. As healthcare systems globally are focusing on delivering more accurate and timely diagnostics, the incorporation of advanced biopsy devices becomes a natural progression. This has expanded the market for these devices while ensuring broader access to high-quality diagnostic procedures for patients, thus providing a positive thrust to the market growth.
Surgical biopsy dominates the market
Surgical biopsy is widely preferred among healthcare professionals for accurate and comprehensive tissue analysis due to its high diagnostic accuracy and versatility. Unlike other biopsy methods, such as needle or liquid biopsies, surgical biopsies enable the removal of an entire tumor or a larger section of tissue, providing a more comprehensive sample for analysis. This increased sample size enhances the ability of pathologists to make accurate and definitive diagnoses, particularly in complex cases where malignancy is suspected but not confirmed through less invasive methods. Additionally, surgical biopsies are often employed in locations difficult to access by needle-based techniques, such as deeper tissues or organs. Another major contributing aspect is its utility beyond diagnosis; it often serves as both a diagnostic and therapeutic procedure by allowing for the complete excision of small malignant masses. The surgical approach is also favored in cases requiring immediate intervention or when other biopsy methods have yielded inconclusive results, thus supporting the segment growth.
Biopsy guidance systems represent the most popular product
Biopsy guidance systems are crucial in enhancing the accuracy and efficiency of biopsy procedures. These guidance systems often integrate with imaging technologies like ultrasound, MRI, or CT scans to provide real-time visualization of the tissue area being targeted. Such integration allows healthcare professionals to precisely locate and assess the tissue sample needed for diagnosis, thereby reducing the risk of complications and procedural errors. In a medical landscape where precision is paramount, these guidance systems offer a significant edge. Their utility is especially prominent in complex cases where the targeted tissue is located deep within the body or near critical organs, where pinpoint accuracy is essential. Moreover, guidance systems are becoming increasingly user-friendly and compatible with various types of biopsy devices, which promotes their adoption across different healthcare settings. By facilitating quicker, more accurate, and safer procedures, biopsy guidance systems are indispensable tools that clinicians rely on, which is fueling the segment growth.
Breast biopsy accounts for the majority of the market share
The main factor driving the growth of this segment is the high incidence of breast cancer globally. According to the World Cancer Research Fund, breast cancer is the most commonly occurring cancer in women and the second most common cancer overall. Early detection is critical for effective treatment, and biopsy remains one of the most reliable diagnostic methods for confirming the presence or absence of cancerous cells in breast tissue. Furthermore, advances in imaging technologies such as mammography and ultrasound have significantly improved the accuracy of breast biopsies, making it a preferred diagnostic option. Public awareness campaigns about the importance of early detection have also played a role in the frequent utilization of breast biopsy procedures. Increasingly, women are becoming proactive about their breast health, leading to more screenings and, subsequently, more biopsies to confirm or rule out malignancy. As a result, the breast biopsy segment continues to maintain its leading position in the biopsy devices market.
Ultrasound guided biopsy holds the largest share in the market
Ultrasound-guided biopsy provides real-time imaging, allowing healthcare professionals to visualize the exact area from which the tissue sample is to be extracted. This enhances the accuracy and efficiency of the biopsy procedure. Moreover, ultrasound-guided biopsies are less invasive and generally quicker than other methods, requiring only local anesthesia. This further improves patient comfort and reduces recovery time. Compared to other imaging modalities like MRI or CT scans, ultrasound is considerably less expensive and more widely available across healthcare settings, including smaller clinics and outpatient centers. This accessibility makes it a go-to option for many physicians. Besides this, ultrasound does not involve exposure to ionizing radiation, making it a safer alternative for repeated procedures and specific patient populations, such as pregnant women. Due to these advantages-real-time imaging, cost-effectiveness, minimal invasiveness, and safety-ultrasound-guided biopsy is widely preferred, contributing to segment growth.
Hospitals and clinics are often the first point of contact for patients requiring diagnostic procedures, including biopsies. These healthcare settings are equipped with advanced diagnostic tools and skilled professionals capable of performing a wide range of biopsy types. The growing incidence of diseases requiring biopsies, coupled with the expansion of healthcare infrastructure globally, has led to higher adoption of biopsy devices in these institutions. Moreover, hospitals often have the financial capacity to invest in the latest biopsy technologies, further augmenting the market growth.
Although smaller in market share compared to hospitals and clinics, academic and research institutes are an essential segment. These institutions primarily focus on research and development activities aimed at improving biopsy technologies or devising new diagnostic methods. They may also conduct clinical trials to evaluate the efficacy of new biopsy devices. While the volume of biopsies performed may be lower compared to hospitals, their influence on product innovation and validation is significant.
North America exhibits a clear dominance in the market
The market research report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share.
North America held the biggest market share since the region has a high prevalence of lifestyle-related diseases, including cancer, necessitating frequent utilization of biopsy procedures for diagnosis and monitoring. According to the American Cancer Society, in 2021, an estimated 1.9 million new cancer cases were diagnosed in the United States alone. In addition, North America boasts a highly developed healthcare infrastructure, including hospitals and clinics equipped with advanced diagnostic technologies, thereby facilitating the adoption of state-of-the-art biopsy devices.
Apart from this, the region has significant investments in healthcare research and development, often leading the way in medical innovation, including the development of new and more effective biopsy techniques and devices. Furthermore, there is a strong insurance framework supporting medical procedures, including biopsies, which makes these diagnostic tests more accessible to a broader population. Also, high levels of public awareness about the importance of early diagnosis and preventive healthcare catalyze the demand for diagnostic procedures such as biopsies. These combined factors position North America as the leading regional market for biopsy devices.
The market is experiencing steady growth as key players are actively engaged in a range of strategic activities aimed at consolidating their market position. These actions include the development of technologically advanced devices, such as vacuum-assisted and image-guided biopsy systems, to increase accuracy and patient comfort. Companies are also focusing on mergers, acquisitions, and strategic collaborations to expand their product portfolios and geographic reach. Additionally, significant investment is being made in research and development (R&D) to innovate new products and improve existing ones. Regulatory approvals and patent filings are other critical areas of focus aimed at securing exclusivity for innovative devices. Through these combined efforts, key market players are shaping the trajectory of the biopsy devices industry.
The market research report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include: